Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.40 | 0.07 | 0.00 |
| FCF Yield | -14.93% | -19.09% | -23.01% | -101.13% |
| EV / EBITDA | -4.78 | -4.58 | 0.00 | -4.81 |
| Quality | ||||
| ROIC | -19.95% | -30.20% | -21.57% | -11.70% |
| Gross Margin | 0.00% | 100.00% | 0.00% | -1,300.42% |
| Cash Conversion Ratio | 0.65 | 0.99 | 0.97 | 2.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 552.78% | -100.00% | 89,486.58% |
| Free Cash Flow Growth | 56.16% | -13.32% | 39.86% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | 0.28 | 0.00 | 2.55 |
| Interest Coverage | -11.38 | -33,338.69 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.02 | 0.00 | -0.00 |
| Cash Conversion Cycle | -525.44 | -28,089.41 | 0.00 | 1,026,247.65 |